Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Royalty Pharma (Nasdaq: RPRX) will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before U.S. markets open.
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Investors can obtain conference call details and view the live webcast via the company's Investors page, and a replay will be archived on the site for at least 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RPRX
On Jan 21, the first trading day after this news, RPRX closed 1.61% above the previous close.
Data tracked by StockTitan Argus for the Jan 21 session.
Key Figures
- Earnings date
- February 11, 2026
- Q4 and full-year 2025 results announcement before U.S. market open
- Current price
- $39.55
- Last close before earnings date announcement; RPRX on Nasdaq
- 2025 royalty transactions
- $4.7 billion
- Royalty transactions announced in 2025 per Jan 12, 2026 update
- Capital deployment 2025
- $2.6 billion
- Capital deployed within 2025 transaction activity
- 2025 Portfolio Receipts guidance
- $3,200–$3,250 million
- Guidance implying 14%–16% growth for 2025
- ROIC
- 15.7%
- Trailing twelve-month Return on Invested Capital reported Jan 12, 2026
- ROIE
- 22.9%
- Trailing twelve-month Return on Incremental Equity
- Quarterly dividend
- $0.235 per share
- First-quarter 2026 dividend, a 6.8% increase vs prior quarter
Historical Context
-
JPM Healthcare Conference business update and 2025 guidance commentary.
-
Up to $500M agreement with Teva to fund TEV-’408 development.
-
Announced higher first-quarter 2026 dividend of $0.235 per share.
-
Acquired remaining Evrysdi royalty interest for $240M plus milestones.
-
Acquired Nuvalent royalty interests in neladalkib and zidesamtinib.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.